Meds & supplements › Quizartinib
Medicine
Quizartinib
VANFLYTA is indicated in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy
Selected manufacturer label information, organised into consistent sections by Sofidex. This source is written for healthcare professionals; ask your pharmacist to explain instructions that are unclear. Read the full label at DailyMed ↗
Drug facts
- Used for
- VANFLYTA is indicated in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy
- Do not take if
- VANFLYTA is contraindicated in patients with severe hypokalemia, severe hypomagnesemia, long QT syndrome, or in patients with a history of ventricular arrhythmias or torsades de pointes.
What it is used for
VANFLYTA is indicated in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 internal tandem duplication (ITD)-positive as detected by an FDA-approved test.
Side effects, and when to stop
The following clinically significant adverse reactions are described elsewhere in the labeling:
- QT Prolongation, Torsades de Pointes, and Cardiac Arrest
Who should not take it
VANFLYTA is contraindicated in patients with severe hypokalemia, severe hypomagnesemia, long QT syndrome, or in patients with a history of ventricular arrhythmias or torsades de pointes.
Storing it
Store at 20°C to 25°C (68°F to 77°F); excursions permitted from 15°C to 30°C (59°F to 86°F).
Cite this page
- NLM
sofidex [Internet]. Daloreum; c2026. Quizartinib; [reviewed 2026 Aug 3; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/quizartinib
- APA 7th
sofidex. (2026, August 3). Quizartinib. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/quizartinib
- AMA 11th
Quizartinib. sofidex. Reviewed August 3, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/quizartinib
The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.